Together, we innovate, we impact, we grow ! At Debiopharm, every step we take is guided by one purpose: improving the lives of people affected by cancer and infectious diseases. As a privately-owned Swiss biopharmaceutical company,
Visium combines strategy, frontier AI, and deep regulated-industry expertise to build and deploy AI-native systems that reinvent how businesses operate - unlocking the value of AI at scale. Were not a strategy firm that ships slide
At Debiopharm, every step we take is guided by one purpose: improving the lives of people affected by cancer and infectious diseases. As a privately-owned Swiss biopharmaceutical company, we’re driven by science, but above all, by
At Debiopharm you will be at the forefront of the fight against cancer and infectious diseases, and you will have the opportunity to work on new innovative medicines for patients. Efficacy is our mode of action,
Research challenge The Research Challenge: AI training costs are exploding, largely due to energy and bandwidth inefficiencies in current electrical datacenters. Our group is developing a novel Optical Circuit Switched (OCS) architecture that drastically reduces power and